Camtek Ltd. Investors Interest Sparks Major Stock Momentum (NASDAQ:CAMT)

Camtek Ltd. (NASDAQ:CAMT)

With the global sales of semiconductors expectancy to reach over $25.87 billion in 2013, let’s take as look at Camtek Ltd. ticker symbol CAMT. Camtek Ltd. specializes in providing automated and technologically advanced solutions concerning semiconductors, printed circuit boards and integrated circuit substrates industries. In the financial markets, this Company has skyrocketed +67.55% Up 1.79 generating over 11.4 million shares in play Monday November 25, 2013 11:00AM EST. Why is Camtek stock Up you ask?

The Company (www.camtek.co.il) has a outstanding $21 million in cash balance sheet with a debt of $817, 000. Camtek guidance concerning Q4 was in such great shape that the Company called for a +11% sequential increase concerning sales. This Company could be potentially on track, since global semiconductor sales have increased over the last six months. Need I not forget to mention that, Camtek is expected long term growth as they hope to successfully launch a 3-D Printer next year.

****

Prima Biomed Ltd. (NASDAQ:PBMD)

As the global market concerning cancer therapeutics is expected to reach over of $110.6 billion in 2013, check out Prima Biomed ticker symbol PBMD.  Prima Biomed specializes in immunocellular therapeutic products in reference towards the treatment of cancer. In the stock markets, this Company has escalated +44.44% Up 0.48 generating over 1.5 million shares in play Monday November 25, 2013 11:00AM EST. What’s pushing the stock Up you ask?

The answer would assumptionally be investor momentum, concerning the significance of CVac™ clinical development program. The Company (www.primabiomed.com.au) reported  all progression-free survival data from its CAN-003 protocol for the treatment of epithelial ovarian cancer in remission after standard 1st or 2nd line treatment. In twenty patients in 2nd remission on the CAN-003 trial, CVac™ clinical development program bestowed roughly a +50% increase in progression free survival as compared to observation only (7.69 months versus 5.14 months; HR=0.41; p=0.09). This is huge for reason being that ovarian cancer is extremely difficult to treat.

Remember: Always do your homework and consult your own financial professional.

Read Full Disclaimer at http://crweselect.com/disclaimer/